1. Wong, C.X., et al., Epidemiology of atrial fibrillation: the Australian and Asia-Pacific perspective. Heart, Lung and Circulation, 2017. 26(9): p. 870-879.
2. Hindricks, G., et al., 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European heart journal, 2021. 42(5): p. 373-498.
3. Mathew, J.S., et al., Fibroblast growth factor-23 and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS). Circulation, 2014. 130(4): p. 298-307.
4. Alonso, A., et al., Circulating fibroblast growth factor-23 and the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities study. Journal of the American Heart Association, 2014. 3(5): p. e001082.
5. Mehta, R., et al., Association of fibroblast growth factor 23 With atrial fibrillation in chronic kidney disease, from the Chronic Renal Insufficiency Cohort Study. JAMA Cardiology, 2016. 1(5): p. 548-556.
6. Patel, S., et al., GDF15 Provides an Endocrine Signal of Nutritional Stress in Mice and Humans. Cell Metab, 2019. 29(3): p. 707-718.e8.
7. Santema, B.T., et al., The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. Clin Res Cardiol, 2020. 109(3): p. 331-338.
8. Shao, Q., et al., Circulating serum levels of growth differentiation factor-15 and neuregulin-1 in patients with paroxysmal non-valvular atrial fibrillation. Int J Cardiol, 2014. 172(2): p. e311-3.
9. Lamprea-Montealegre, J.A., et al., Cardiac Biomarkers and Risk of Atrial Fibrillation in Chronic Kidney Disease: The CRIC Study. J Am Heart Assoc, 2019. 8(15): p. e012200.
10. Rienstra, M., et al., Relation between soluble ST2, growth differentiation factor-15, and high-sensitivity troponin I and incident atrial fibrillation. Am Heart J, 2014. 167(1): p. 109-115 e2.
11. Alonso, A., et al., Circulating fibroblast growth factor-23 and the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities study. J Am Heart Assoc, 2014. 3(5): p. e001082.
12. Mizia-Stec, K., et al., Lower soluble Klotho and higher impact fibroblast growth factor 23 serum levels are associated with episodes of atrial fibrillation. European Heart Journal, 2017. 38: p. 637.
13. Bening, C., et al., Atrial contractility and fibrotic biomarkers are associated with atrial fibrillation after elective coronary artery bypass grafting. Journal of Thoracic and Cardiovascular Surgery, 2020. 159(2): p. 515-523.
14. Liu, X., et al., Fluoroquinolones increase the risk of serious arrhythmias: A systematic review and meta-analysis. Medicine (Baltimore), 2017. 96(44): p. e8273.
15. Zhu, W., et al., Association of Physical Fitness With the Risk of Atrial Fibrillation: A Systematic Review and Meta-Analysis. Clin Cardiol, 2016. 39(7): p. 421-8.
16. Luo, D., et al., Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res, 2018. 27(6): p. 1785-1805.
17. Wan, X., et al., Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol, 2014. 14: p. 135.
18. Greenland, S. and M.P. Longnecker, Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. American Journal of Epidemiology, 1992. 135(11): p. 1301-9.
19. Xu, C. and D. Sar, The robust error meta-regression method for dose-response meta-analysis. International journal of evidence-based healthcare, 2017. 16(3): p. 138.
20. Xu, C., et al., Flexible piecewise linear model for investigating doseresponse relationship in meta-analysis: methodology,
examples, and comparison. PeerJ Preprints, 2018. 6:e27277v1.
21. Xu, C., et al., The methodological quality of dose-response meta-analyses needed substantial improvement: a cross-sectional survey and proposed recommendations. J Clin Epidemiol, 2019. 107: p. 1-11.
22. Liu, X., et al., The obesity paradox for outcomes in atrial fibrillation: Evidence from an exposure-effect analysis of prospective studies. Obes Rev, 2020. 21(3): p. e12970.
23. Liu, X., et al., Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis. Clin Cardiol, 2020.
24. Svennberg, E., et al., NT-proBNP is a powerful predictor for incident atrial fibrillation - Validation of a multimarker approach. Int J Cardiol, 2016. 223: p. 74-81.
25. Bening, C., et al., Atrial contractility and fibrotic biomarkers are associated with atrial fibrillation after elective coronary artery bypass grafting. J Thorac Cardiovasc Surg, 2020. 159(2): p. 515-523.
26. Bouchot, O., et al., Low Circulating Levels of Growth Differentiation Factor-15 Before Coronary Artery Bypass Surgery May Predict Postoperative Atrial Fibrillation. J Cardiothorac Vasc Anesth, 2015. 29(5): p. 1131-9.
27. Smit, M.D., et al., Role of inflammation in early atrial fibrillation recurrence. Europace, 2012. 14(6): p. 810-7.
28. Wei, Y., et al., The Predictive Value of Growth Differentiation Factor-15 in Recurrence of Atrial Fibrillation after Catheter Ablation. Mediators Inflamm, 2020. 2020: p. 8360936.
29. Chen, J.M., et al., Significance of serum fibroblast growth factor-23 and miR-208b in pathogenesis of atrial fibrillation and their relationship with prognosis. World J Clin Cases, 2020. 8(16): p. 3458-3464.
30. Maan, A., et al., Association between Heat Shock Protein-60 and Development of Atrial Fibrillation: Results from the Multi-Ethnic Study of Atherosclerosis (MESA). PACE - Pacing and Clinical Electrophysiology, 2016. 39(12): p. 1373-1378.
31. Mizia-Stec, K., et al., Lower soluble Klotho and higher fibroblast growth factor 23 serum levels are associated with episodes of atrial fibrillation. Cytokine, 2018. 111: p. 106-111.
32. Maan, A., et al., Association between Heat Shock Protein-60 and Development of Atrial Fibrillation: Results from the Multi-Ethnic Study of Atherosclerosis (MESA). Pacing Clin Electrophysiol, 2016. 39(12): p. 1373-1378.
33. Mehta, R., et al., Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study. JAMA Cardiol, 2016. 1(5): p. 548-56.
34. Lamprea-Montealegre, J.A., et al., Cardiac Biomarkers and Risk of Atrial Fibrillation in Chronic Kidney Disease: The CRIC Study. Journal of the American Heart Association, 2019. 8(15).
35. Wei, Y., et al., The Predictive Value of Growth Differentiation Factor-15 in Recurrence of Atrial Fibrillation after Catheter Ablation. Mediators of Inflammation, 2020. 2020.
36. Molvin, J., et al., Exploration of pathophysiological pathways for incident atrial fibrillation using a multiplex proteomic chip. Open Heart, 2020. 7(1): p. e001190.
37. Hijazi, Z., et al., Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart, 2016. 102(7): p. 508-17.
38. Wallentin, L., et al., Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation, 2014. 130(21): p. 1847-58.
39. Miyamura, M., et al., Circulating fibroblast growth factor 23 has a U-shaped association with atrial fibrillation prevalence. Circulation Journal, 2015. 79(8): p. 1742-1748.
40. Alonso, A., et al., Circulating fibroblast growth factor‐23 and the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities study. Journal of the American Heart Association, 2014. 3(5): p. e001082.
41. Meng, L., et al., Predictive value of circulating fibroblast growth factor-23 on atrial fibrillation: A meta-analysis. Int J Cardiol, 2016. 210: p. 68-71.
42. Hannan, M., et al., Risk Factors for CKD Progression: Overview of Findings from the CRIC Study. Clin J Am Soc Nephrol, 2020.
43. Neyra, J.A., M.C. Hu, and O.W. Moe, Klotho in Clinical Nephrology: Diagnostic and Therapeutic Implications. Clin J Am Soc Nephrol, 2020. 16(1): p. 162-176.
44. Hu, M.C., et al., Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J Am Soc Nephrol, 2015. 26(6): p. 1290-302.
45. Miyamura, M., et al., Circulating Fibroblast Growth Factor 23 Has a U-Shaped Association With Atrial Fibrillation Prevalence. Circ J, 2015. 79(8): p. 1742-8.
46. Stiles, M.K., et al., Paroxysmal lone atrial fibrillation is associated with an abnormal atrial substrate: characterizing the “second factor”. Journal of the American College of Cardiology, 2009. 53(14): p. 1182-1191.
47. Pi, M., et al., Cardiovascular Interactions between Fibroblast Growth Factor-23 and Angiotensin II. Sci Rep, 2018. 8(1): p. 12398.
48. Si, W., et al., Fibroblast growth factor type 1 receptor stimulation of T-type Ca(2+) channels in sensory neurons requires the phosphatidylinositol 3-kinase and protein kinase A pathways, independently of Akt. Cell Signal, 2018. 45: p. 93-101.
49. Weinman, E.J., et al., Fibroblast growth factor-23-mediated inhibition of renal phosphate transport in mice requires sodium-hydrogen exchanger regulatory factor-1 (NHERF-1) and synergizes with parathyroid hormone. J Biol Chem, 2011. 286(43): p. 37216-21.
50. Nattel, S., Molecular and Cellular Mechanisms of Atrial Fibrosis in Atrial Fibrillation. JACC Clin Electrophysiol, 2017. 3(5): p. 425-435.
51. Tuegel, C., et al., GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD. Am J Kidney Dis, 2018. 72(4): p. 519-528.
52. Wollert, K.C., T. Kempf, and L. Wallentin, Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. Clin Chem, 2017. 63(1): p. 140-151.
53. Nopp, S., et al., Growth differentiation factor-15 predicts major adverse cardiac events and all-cause mortality in patients with atrial fibrillation. Eur J Intern Med, 2021. 88: p. 35-42.
54. Berg, D.D., et al., Performance of the ABC scores for assessing the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48. Circulation, 2019. 139(6): p. 760-771.
55. Hijazi, Z., et al., A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J, 2018. 39(6): p. 477-485.
56. Pol, T., et al., Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. Open Heart, 2021. 8(1).
57. Hijazi, Z., et al., The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet, 2016. 387(10035): p. 2302-2311.